{"doi":"10.1002/eji.202250133","title":"YF17D‐based vaccines – standing on the shoulders of a giant","abstract":"<jats:title>Summary</jats:title>\n                  <jats:p>Live‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single‐dose immunization. More recently, progress in molecular virology and synthetic biology allowed engineering of YF17D as a powerful vector and promising platform for the development of novel recombinant live vaccines, including two licensed vaccines against Japanese encephalitis and dengue, even in paediatric use. Likewise, numerous chimeric and transgenic preclinical candidates have been described. These include prophylactic vaccines against emerging viral infections (e.g. Lassa, Zika and SARS‐CoV‐2) and parasitic diseases (e.g. malaria), as well as therapeutic applications targeting persistent infections (e.g. HIV and chronic hepatitis), and cancer. Efforts to overcome historical safety concerns and manufacturing challenges are ongoing and pave the way for wider use of YF17D‐based vaccines. In this review, we summarize recent insights regarding YF17D as vaccine platform, and how YF17D‐based vaccines may complement as well as differentiate from other emerging modalities in response to unmet medical needs and for pandemic preparedness.</jats:p>","journal":"European Journal of Immunology","year":2024,"id":631749,"datarank":0.6023342422139282,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.1529744011808295,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.1529744011808295,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":15,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":618956,"name":"Yeranddy A. Alpízar","orcid":"0000-0003-1959-5393","position":1,"is_corresponding":false},{"id":1042982,"name":"Ji Ma","orcid":"0000-0002-0912-2632","position":2,"is_corresponding":false},{"id":616295,"name":"Lotte Coelmont","orcid":"0000-0002-7888-4534","position":3,"is_corresponding":false},{"id":218411,"name":"Kai Dallmeier","orcid":"0000-0002-8117-9166","position":4,"is_corresponding":false},{"id":1637304,"name":"Lorena Sanchez‐Felipe","orcid":"0000-0002-6928-0931","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"YF17D‐based vaccines – standing on the shoulders of a giant","abstract":"<jats:title>Summary</jats:title>\n                  <jats:p>Live‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single‐dose immunization. More recently, progress in molecular virology and synthetic biology allowed engineering of YF17D as a powerful vector and promising platform for the development of novel recombinant live vaccines, including two licensed vaccines against Japanese encephalitis and dengue, even in paediatric use. Likewise, numerous chimeric and transgenic preclinical candidates have been described. These include prophylactic vaccines against emerging viral infections (e.g. Lassa, Zika and SARS‐CoV‐2) and parasitic diseases (e.g. malaria), as well as therapeutic applications targeting persistent infections (e.g. HIV and chronic hepatitis), and cancer. Efforts to overcome historical safety concerns and manufacturing challenges are ongoing and pave the way for wider use of YF17D‐based vaccines. In this review, we summarize recent insights regarding YF17D as vaccine platform, and how YF17D‐based vaccines may complement as well as differentiate from other emerging modalities in response to unmet medical needs and for pandemic preparedness.</jats:p>","is_dataset_classified":null,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38571392","pmcid":null,"openalex_id":"https://openalex.org/W4393943624","authors":[],"funders":[{"funder_name":"Bill and Melinda Gates Foundation","grant_id":"INV‐00636","title":null},{"funder_name":"Flemish Research Foundation (FWO) Excellence of Science (EOS) program","grant_id":"40007527","title":null},{"funder_name":"European Union's Horizon 2020 research and innovation program","grant_id":"RABYD-VAX","title":null},{"funder_name":"European Union's Horizon 2020 research and innovation program","grant_id":"733176","title":null},{"funder_name":"European Health Emergency Preparedness and Response Authority (HERA)","grant_id":"C3/19/057","title":null},{"funder_name":"Bill and Melinda Gates Foundation","grant_id":"INV-00636","title":null},{"funder_name":"Flemish Research Foundation (FWO) Excellence of Science (EOS) program","grant_id":"VirEOS2","title":null},{"funder_name":"European Commission","grant_id":"101137459","title":"Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design"}],"total_grants":8,"fwci":7.766,"citation_percentile":0.97988251,"influential_citations":0,"citation_trend":[{"year":2024,"count":5},{"year":2025,"count":8},{"year":2026,"count":6}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eji.202250133","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eji.202250133","host_type":"HYBRID"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eji.202250133","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/eji.202250133","host_type":"publisher"},{"url":"https://doi.org/10.1002/eji.202250133","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38571392","host_type":"repository"},{"url":"https://lirias.kuleuven.be/handle/20.500.12942/740533","host_type":"repository"},{"url":"https://lirias.kuleuven.be/retrieve/4149d3b3-0dc2-4203-8644-046b2398e190","host_type":"repository"},{"url":"http://dx.doi.org/10.1002/eji.202250133","host_type":""}],"fields_of_study":["Mosquito-borne diseases and control","Viral Infections and Outbreaks Research","Virology and Viral Diseases","Medicine","Biology","0301 basic medicine","03 medical and health sciences"],"mesh_terms":["Animals","Humans","Vaccination","Vaccines, Attenuated","Yellow Fever","Yellow fever virus","Yellow Fever Vaccine"],"keywords":["Dengue vaccine","Virology","Immunogenicity","Biology","Immunology","Immunization","Lassa virus","Malaria","Vaccination","Dengue fever","Virus","Dengue virus","Immune system","Emerging Infectious Diseases","Therapeutic Vaccines","Systems Vaccinology","Live‐attenuated Recombinant Vaccines","Yellow Fever Vaccine (Yf17d)","LONG-TERM IMMUNITY","Vaccines, Attenuated","DOUBLE-BLIND","ATTENUATED VACCINE","Yellow Fever","Humans","Animals","YELLOW-FEVER VACCINE","Science & Technology","T-CELL RESPONSES","HAMSTER MESOCRICETUS-AURATUS","Yellow Fever Vaccine","INDIAN RHESUS MACAQUES","BORNE ENCEPHALITIS-VIRUS","3204 Immunology","1107 Immunology","Yellow fever virus","Life Sciences & Biomedicine","Live-attenuated recombinant vaccines","CHIMERIC VIRUS-VACCINE"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T00:36:38.159862Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}